JBJ-08-178-01
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 2401867-58-9
- Formula: C31H30N8O3
- Molecular Weight:562.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
20.44 nM
Compound: JBJ-08-178-01
|
Antiproliferative activity against mouse BaF3 cells harboring HER2 YVMA mutant by CellTiter-Glo assay
Antiproliferative activity against mouse BaF3 cells harboring HER2 YVMA mutant by CellTiter-Glo assay
|
[PMID: 38518121] |
Chemical Information
-
CAS No. 2401867-58-9
-
Molecular Weight 562.62
-
Formula C31H30N8O3
-
SMILES
CC1=CC(NC2=C3C=C(NC(/C=C/CN(C)C)=O)C(OCC)=CC3=NC=C2C#N)=CC=C1OC4=CC5=NC=NN5C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Rubin E, et al. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. Int J Mol Sci. 2024 Jan 15;25(2):1064. [Content Brief]
[2]. Vathiotis IA, et al. Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond. Cancers (Basel). 2023 Feb 17;15(4):1286. [Content Brief]
[3]. Son J, et al. A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Res. 2022 Apr 15;82(8):1633-1645. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JBJ-08-178-01 Related Classifications
HY-164487 Related Classifications
Powered by Bioz